The Discounted Cash Flow (DCF) valuation of Lyra Therapeutics Inc (LYRA) is (616.59) USD. With the latest stock price at 0.50 USD, the upside of Lyra Therapeutics Inc based on DCF is -124664.3%.
Based on the latest price of 0.50 USD and our DCF valuation, Lyra Therapeutics Inc (LYRA) is a sell. selling LYRA stocks now will result in a potential gain of 124664.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.7% - 7.1% | 6.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (2,004.38) - (370.81) | (616.59) |
| Upside | -405024.4% - -75010.6% | -124664.3% |